The unprocessed data is available from GEO and ArrayExpress databases. The GEO and ArrayExpress projects accession numbers, the processed data and all result data are available online at <https://life.bsc.es/iconbi/MultiScaleNN/index.html>.

Introduction {#sec001}
============

A disease is often described by symptoms and affected tissues. However, to give a definite diagnosis, physicians often need to analyse patient samples (e.g., blood samples, or biopsies) for characteristic disease indicators, commonly referred to as disease biomarkers. These may include disregulated genes, or pathways \[[@pone.0231059.ref001], [@pone.0231059.ref002]\]. Taking into consideration the history of a patient's past and present conditions identifying genetic predispositions, as well as considering associations between diseases, aid in achieving accurate diagnostics and treatments \[[@pone.0231059.ref003]\]. By also taking advantage of the increasing availability of large scale molecular data, precision medicine aims at improving the understanding of the molecular base of diseases on individual basis, as well as the relationships between different conditions \[[@pone.0231059.ref004], [@pone.0231059.ref005]\]. The benefits from such work are multiple and include drug re-purposing and identification of new disease biomarkers to improve treatments and diagnoses.

Many studies have investigated disease--gene and disease--pathway associations with the objective of improving diagnoses \[[@pone.0231059.ref006]--[@pone.0231059.ref009]\]. For instance, Zhao *et al*. \[[@pone.0231059.ref008]\] propose a ranking of disease genes based on gene expression and protein interactions using Katz-centrality. Hong *et al*. \[[@pone.0231059.ref009]\] design a tool that identifies significantly disrupted pathways by comparing patient gene expression against controls collected from other experiments. Cogswell *et al*. \[[@pone.0231059.ref010]\] identify putative gene and pathway biomarkers through change in miRNA in Alzheimer's disease. In specific cancers, Abeel *et al*. \[[@pone.0231059.ref006]\] use support vector machines and ensemble feature selection methods to select putative gene biomarkers. Ciucci *et al*. \[[@pone.0231059.ref011]\] developed a general purpose algorithm based on the analysis of PCA loadings that can be used to identify genes that discriminate between conditions from expression data.

A key issue is that most of these studies consider diseases in isolation, i.e. comparing patients having a disease of interest to healthy individuals while the predicted biomarkers could be shared between various diseases. This limits the discriminative potential of such studies for accurate diagnoses. Indeed, network medicine has shown that diseases can share significant molecular background, as evidenced by numerous studies based on patient historical records \[[@pone.0231059.ref003], [@pone.0231059.ref012], [@pone.0231059.ref013]\], biological knowledge of the diseases \[[@pone.0231059.ref004], [@pone.0231059.ref005], [@pone.0231059.ref014]\], or patient gene expression profiles \[[@pone.0231059.ref015]\]. For instance, Goh *et al*. \[[@pone.0231059.ref004]\] build a disease network, which connects diseases that share at least one gene which when mutated is linked to both conditions. Lee *et al*. \[[@pone.0231059.ref005]\] construct a disease network of metabolic diseases, connecting pairs of diseases for which associated mutated enzymes catalyze adjacent metabolic reactions. Hidalgo *et al*. \[[@pone.0231059.ref012]\] take a different approach by building a disease network based on disease co-morbidities, i.e. two diseases are connected if they tend to co-occur significantly in the patient populations. They used Medicare records of elderly patients to build the network. He *et al*. \[[@pone.0231059.ref014]\] propose PCID (Predicting Comorbidity by Integrating Data), an approach to predict disease co-morbidities by aggregating disease similarity scores derived from different data including protein--protein interactions (PPIs), pathways, and functional annotations.

Sánchez-Valle *et al*. \[[@pone.0231059.ref015]\] define a disease network, named the Disease Molecular Similarity Network (DMSN) based on patient's differential expression profiles. In their study, the DMSN is generated using positive and negative relative molecular similarities (RR) to measure disease similarity and dissimilarity, respectively, that is then interpreted as an estimate of risk. First, a patient-patient similarity network is generated based on the similarities of patient's differential expression profiles. Next, using the relative similarity score, diseases are related to each other. The resulting network is directed and each edge is associated to a positive or negative label indicating either an increased or decreased risk of developing the target disease if the patient has the source disease. The underlying assumption is that having a given disease can increase the risk of developing a disease characterized by a similar gene expression profile.

In these various approaches, a key issue is that either a single data source is used, such as disease--gene mutational data \[[@pone.0231059.ref004]\], or no new biological knowledge about a specific disease could be derived from the results (e.g., PCID \[[@pone.0231059.ref014]\]).

In this work, we propose an integrative framework based on artificial neural networks (NN) to predict disease--disease links, as well as disease--pathway and disease--gene associations. We train the model to predict patients' diagnoses based on differential gene expression. The NN's structure is designed to mimic the cellular multi-scale functional organization by integrating gene--pathway annotations. This approach follows on from a body of work aiming to build neural networks based on prior information defining the structure of the network \[[@pone.0231059.ref016]\]. For instance, Ma *et al*. \[[@pone.0231059.ref017]\] build a neural network using the Gene Ontology \[[@pone.0231059.ref018]\] directed acyclic graph as a template for the connections. The neural network, named DCell, is then trained to predict phenotype related to cellular fitness from genotype data. The trained DCell predicts cellular growth almost as accurately as laboratory observations.

We show that our framework achieves good predicting performances on our dataset. By analysing the trained NN, i.e. the underlying weight matrices, we show that we can extract biological knowledge relevant for each disease. Specifically, we use the trained NN to predict novel disease--pathway and disease--gene links and from those predictions we extract disease similarity score used to identify putative co-morbidities. We show that our predictions are biologically relevant against established ground-truths and verify the top predictions through manual literature curation ensuring that the sources do not use the same data, to mitigate the risk of argument circularity.

1 Material & methods {#sec002}
====================

1.1 Datasets {#sec003}
------------

We use the original dataset of patient gene expressions used by \[[@pone.0231059.ref015]\] in which each patient is associated to a single disease (see [S1 File](#pone.0231059.s001){ref-type="supplementary-material"} for details). For each patient, we define a differential gene expression vector of size corresponding to the number of genes and in which the *i*^*th*^ entry is equal to 1, −1, or 0 depending on whether the *i*^*th*^ gene is significantly (with 5% cut-off) over-, under-, or normally expressed, respectively, for that patient (see [S1 File](#pone.0231059.s001){ref-type="supplementary-material"} for details).

Pathway annotations were collected from Reactome database \[[@pone.0231059.ref019]\] (accessed December 2018). Only the lowest pathways in the hierarchy are considered to avoid dealing with pathway interactions (i.e. pathways containing other pathways). Of those pathways, only the ones that have a Traceable Author Statement (TAS) are kept. In total, we consider 1, 708 pathway annotations.

The final dataset contains 4, 788 samples (patients) diagnosed by one of 83 diseases (see S1 Table in [S1 File](#pone.0231059.s001){ref-type="supplementary-material"} for cohort distribution). In total, 20, 525 genes have their expressions measured, but only a subset is used as input to our method described in the following section, as we restrict ourselves to genes associated to at least one pathway, which leaves 9, 247 genes.

1.2 Neural network based data--integration framework {#sec004}
----------------------------------------------------

We propose a neural network (NN) predicting a patient diagnosis based on differential gene expression. The structure of the neural network is based on molecular organization, more specifically gene--pathway annotations downloaded from Reactome (see [Fig 1](#pone.0231059.g001){ref-type="fig"}). We integrate molecular organization data into our model to reflect the idea that complex diseases, such as cancer, can be the results of the perturbations of groups of genes, as opposed to a single gene. Using Reactome data allows us to incorporate prior knowledge into our model in the form of biologically meaningful groupings of genes.

![Example of neural network architecture.\
For the first layer, the connections are defined by biological information, i.e. a unit representing a gene is connected to all the biological pathways that the gene is involved in. We do not add any prior knowledge on the last layer, thus it is fully connected.](pone.0231059.g001){#pone.0231059.g001}

A neural network can be expressed as a series of matrix multiplications interleaved with non-linear function (See [S1 File](#pone.0231059.s001){ref-type="supplementary-material"} for more details). Here, we use the softmax function \[[@pone.0231059.ref020]\] as the last non-linear function of the NN (common choice for multiclass classification problems) and the hyperbolic tangent non-linear function for hidden layers to allow a hidden unit to have values lying in \[−1, 1\] to represent up- and down-regulations. We use the classical cross-entropy function to define the loss function. Our neural network architecture has only one hidden layer capturing gene--pathway links. Hereafter, we refer to this model as GPD (for Gene--Pathway--Disease).

As reference model, we use a multiclass logistic regression (MLR; no hidden layer). MLR and GPD have a different number of parameters (or free weights): (573, 314) for MLR and (137, 838) for GPD. Note that, due to this imbalance, we do not expect GPD to outperform MLR in the diagnosis prediction task.

To train both GPD and MLR, we first perform a 10-fold cross-validation to fix the number of training epochs. To fix the number of training epochs, we compute the average number of epochs at which the test loss is the smallest across the runs (see S1 Fig and S2 Fig in [S1 File](#pone.0231059.s001){ref-type="supplementary-material"}). As the dataset is imbalanced, we use stratification to split the data, ensuring that at least one patient per disease is in the test set. Using this number of epochs, we perform another 10-fold cross-validation to evaluate the performance of our models. We use the Adam optimizer \[[@pone.0231059.ref021]\] with learning rate 0.01 and the layer weights are initialized to small values using the initialization process proposed by He *et al*. \[[@pone.0231059.ref022]\]. We investigated the addition of classical regularisation techniques---L1, L2, and dropout regularisation---as a mean to reduce the capacity of the model to overfit. We found that the performances were better without any regularisations (see S2 Table in [S1 File](#pone.0231059.s001){ref-type="supplementary-material"}).

The neural networks are implemented with Tensorflow \[[@pone.0231059.ref023]\].

1.3 Predicting disease--disease, disease--pathway, and disease--gene relationships {#sec005}
----------------------------------------------------------------------------------

To identify associations between diseases and genes or pathways, we perform sensitivity analysis \[[@pone.0231059.ref024]\] (see [S1 File](#pone.0231059.s001){ref-type="supplementary-material"}). The association score between disease *d* and unit *u* (representing a gene, or a pathway) is measured by the intensity of the local variation of the output unit associated with *d* with respect to perturbation of *u*. Intuitively, this score measures how the prediction score of disease *d* is affected by disregulation of a gene/pathway: we quantify the change in one disease score induced by a disregulation in the gene expression, or pathway activation. We test this scoring approach for the prediction of disease--gene and disease--pathway associations. In particular, we rank disease--gene and disease--pathway pairs based on this score and test if the score correlates with known associations through a Precision-Recall and Receiver Operating Characteristic (ROC) analysis. Score thresholds could be inferred from the precision-recall curves. These thresholds would be uninformative in general since they are tied to specific runs and datasets. Hence, we focus on manual validation of the top scoring associations.

Based on this score, we represent each disease by a set formed by the *k*~*genes*~ highest scoring genes and a set containing the *k*~*pathways*~ highest scoring pathways. We then score disease--disease associations using the Jaccard Index of their sets. The Jaccard Index of two sets *S*~1~ and *S*~2~ is defined as $\frac{|S_{1} \cap S_{2}|}{|S_{1} \cup S_{2}|}$, where \|⋅\| represents the cardinality of a set. Following on from similar approach used in DisGeNET \[[@pone.0231059.ref025]\], we interpret those associations as co--morbidities. The number of highest scoring pathways and genes considered is set to 150 and 300, respectively, as those numbers gave the best results.

2 Results & discussion {#sec006}
======================

2.1 Classification performances {#sec007}
-------------------------------

To validate the relevance of our model, we verify that the classification performances are at least on par with competing methods: MLR, Random Forest (RF), Bernoulli Naive Bayes (nB), and Support Vector Machine (SVM) algorithms (we use the implementation available through the scikit-learning python package \[[@pone.0231059.ref026]\]). We perform 10-fold cross-validation for the algorithms to fix the hyperparameters (numbers of trees 100, smoothing parameter 0.001 and penalty parameter 100, respectively) and retain the best performing models in terms of cross-entropy loss (the objective function of the neural networks).

We evaluate performances by computing 3 different scores: cross-entropy loss (CEL), micro- and macro-average precision (Pre~*μ*~ and Pre~*M*~). Pre~*μ*~ give a measure of the overall precision of each classifier, while Pre~*M*~ gives an average of the precisions across the different classes (diseases). The details of each score can be found in [S1 File](#pone.0231059.s001){ref-type="supplementary-material"}.

We observe that the neural networks; MLR and GPD, give better, or at least on-par, performances when compared to RF, nB, and SVM classifiers as measured by our three metrics (see [Table 1](#pone.0231059.t001){ref-type="table"}). This observation justifies the relevance of our GPD model. The best model appears to be the multinomial logistic regression (MLR), which corresponds to the most complex neural network model in terms of the number of parameters (or degree of freedom), since MLR has ∼4 times more parameters than GPD. This analysis shows that using biological knowledge to guide the structure of neural networks, in the limit of the models proposed, does not improve classification performance compared to the multiclass logistic regression (MLR) and only offers slight improvement when compared to a RF classifier (see [Table 1](#pone.0231059.t001){ref-type="table"}). However, we show, in the following Sections, that the trained GPD models can be more successfully exploited than MLR to extract biological information. Note as well that the gene--pathway information on which GPD relies is both noisy and incomplete, as biological data often is, and that performances should improve as knowledge improves.

10.1371/journal.pone.0231059.t001

###### Performances of different classifiers in terms of cross-entropy loss (CEL), micro- and macro-average precisions (Pre~*μ*~ and Pre~*M*~, respectively).

Each score is computed across the 10-fold cross-validation and we provide the standard deviation. Bold scores highlight the best scores for each metric.

![](pone.0231059.t001){#pone.0231059.t001g}

  Algorithm   CEL                       Pre~*μ*~                  Pre~*M*~
  ----------- ------------------------- ------------------------- -------------------------
  GPD         1.09±0.06                 0.80±0.01                 0.71±0.02
  MLR         **1.01** **±** **0.07**   **0.84** **±** **0.01**   **0.76** **±** **0.01**
  RF          1.56±0.24                 0.80±0.01                 0.70±0.03
  nB          10.63±0.55                0.66±0.01                 0.60±0.02
  SVM         1.42±0.04                 0.72±0.02                 0.59±0.02

Hereafter, we consider for each model (GPD and MLR) the trained NN that gave the lowest cross-entropy loss during the 10-fold cross validation.

2.2 Our GPD model uncovers molecular mechanisms of diseases {#sec008}
-----------------------------------------------------------

To uncover molecular mechanisms of disease, i.e., genes and pathways that are associated to specific diseases, we extract predictions from MLR and GPD using the approach described in Section 1.3. We test the performance of our disease--pathway and disease--gene associations predictions by comparing against established databases. We investigate the top predictions of the GPD model through manual search of the literature.

### Predicting disease--gene associations {#sec009}

For each model, we compute disease--gene association scores as described in Section 1.3 and we test the validity of our predictions against DisGeNET database \[[@pone.0231059.ref025]\]. We compare the entire set of predictions against two baselines: the Frequency of Differential Expression (FDE) and the approach introduced by Zhao *et al*. \[[@pone.0231059.ref008]\] for *de novo* disease--gene association prediction (Katz). Those methods are detailed in the [S1 File](#pone.0231059.s001){ref-type="supplementary-material"}.

We use precision--recall and ROC curves to evaluate the performance of our approach and compute the areas under the curves (see [Table 2](#pone.0231059.t002){ref-type="table"} and S3 Fig and S4 Fig in [S1 File](#pone.0231059.s001){ref-type="supplementary-material"}). Interestingly, we observe that the FDE score is a poor predictor of disease--gene associations. We further observe that GPD is the best performing models for this task with Katz coming second. The relatively poor overall performances can be partially attributed to the incompleteness of the reported disease--gene associations in DisGeNET. To corroborate this hypothesis, we search the literature for support for the top 10 predicted disease--gene associations by the best performing model, GPD (see [Table 5](#pone.0231059.t005){ref-type="table"}). Note that none of those associations are reported in DisGeNET.

10.1371/journal.pone.0231059.t002

###### Performance in terms of area under the ROC (AUROC) and area under the precision--recall (AUPRE) for the prediction of disease--gene associations for each methods.

![](pone.0231059.t002){#pone.0231059.t002g}

         AUROC      AUPRE
  ------ ---------- ------------------
  GPD    **0.59**   **8.5e**^−**3**^
  MLR    0.52       6.3*e*^−3^
  Katz   0.55       7.3*e*^−3^
  FDE    0.50       5.3*e*^−3^

We are able to find literature support for 70% of the top 10 predicted disease--gene associations (see [Table 3](#pone.0231059.t003){ref-type="table"}). Furthermore, we find indications that some of our top-scoring, non-validated predictions could be relevant, such as the associations of asthma with UBB and amyotrophic lateral sclerosis (ALS) with PSMD13. Ubuquitin B (UBB) belongs to the ubiquitin-proteasome (UPS) and it is known that aberration in the UPS is responsible for inflammatory and autoimmune diseases such as asthma \[[@pone.0231059.ref027]\]. Moreover, ALS onsets occur typically after age 50 and manifest partially through muscle weakness. PSMD13 is linked to aging \[[@pone.0231059.ref028]\] and high expression of the gene has been found in skeletal muscle of athletes \[[@pone.0231059.ref029]\], suggesting that under-expression could be a sign of muscle weakness.

10.1371/journal.pone.0231059.t003

###### Top 10 disease--gene predicted by GPD.

![](pone.0231059.t003){#pone.0231059.t003g}

  Disease                                 Gene     Literature support
  --------------------------------------- -------- --------------------
  Asthma                                  UBB      
  Schizophrenia                           RHOA     PMID:16402129
  Alzheimer's disease                     FGF23    PMID:26674092
  Autistic disorder                       FGF20    PMID:19204725
  Prostate cancer                         RPS27A   PMID:15647830
  Amyotrophic lateral sclerosis           PSMD13   
  Amyotrophic lateral sclerosis           CASP3    PMID:11715057
  Chronic obstructive pulmonary disease   SKP1     PMID:23713962
  Autistic disorder                       PSMB2    
  Irritable bowel syndrome                PSMA1    PMID:28717845

These results validate the relevance of our framework for de novo disease--gene association prediction and confirm the incompleteness of DisGeNET.

### Predicting disease--pathway associations {#sec010}

For our GPD model, we compute disease--pathway association scores as described in Section 1.3 and we test the validity of our predictions by comparison with CTD database \[[@pone.0231059.ref030]\]. As a baseline, we consider disease--pathway scores corresponding to the average FDE (AFDE) of genes within the pathway for patients having the disease.

We evaluate the results as done previously for disease--gene associations (see [Table 4](#pone.0231059.t004){ref-type="table"} and S5 Fig and S6 Fig in [S1 File](#pone.0231059.s001){ref-type="supplementary-material"}). We observe that GPD convincingly outperforms AFDE. The seemingly poor performances of both approaches can partially be attributed to the incompleteness of CTD database. To test this hypothesis, we search the literature for support for the top 10 disease--pathway associations predicted with our GPD (see [Table 5](#pone.0231059.t005){ref-type="table"}). Note that none of these associations predicted are reported in CTD database.

10.1371/journal.pone.0231059.t004

###### Performance in terms of area under the ROC (AUROC) and area under the precision--recall (AUPRE) for the prediction of disease--pathway associations for each methods.

![](pone.0231059.t004){#pone.0231059.t004g}

         AUROC      AUPRE
  ------ ---------- ----------------
  GPD    **0.53**   **8e**^−**2**^
  AFDE   0.47       6*e*^−2^

10.1371/journal.pone.0231059.t005

###### Top 10 disease--pathway predictions derived from GPD.

![](pone.0231059.t005){#pone.0231059.t005g}

  Disease                     Pathway R-HSA-   Literature support
  --------------------------- ---------------- ------------------------------------------------------------------------------------
  Autistic disorder           5653890          
  Irritable bowel syndrome    532668           PMID:20338921
  Irritable bowel syndrome    391906           PMID:16835707
  Type 2 diabetes mellitus    499943           doi:[10.2337/diabetes.51.2007.S363](https://doi.org/10.2337/diabetes.51.2007.S363)
  Asthma                      391906           PMID:8603274
  Schizophrenia               71288            PMID:22465051
  Major depressive disorder   8934903          PMID:27063986
  Type 2 diabetes mellitus    8939245          PMID:19667185
  Schizophrenia               5683371          
  Sjogren's syndrome          389661           

We find literature support for 7 out of the top 10 predicted disease--pathway associations (see [Table 5](#pone.0231059.t005){ref-type="table"}). Furthermore, we find indications that some of our top-scoring, non-validated predictions could be relevant, such as the association of autistic disorder with the lactose synthesis pathway (R-HSA-5653890) and the association of Schizophrenia with pathway R-HSA-5683371 linked to microphtalmia. The lactose synthesis pathway (R-HSA-5653890) contains three genes: LALBA, SLC2A1, and B4GALT1. All of those genes might be associated with autistic disorders. One patented method to detect autistic disorder (US20140349977A1) includes LALBA as one of the genes of interest. SLC2A1 mutation has been reported in patients diagnosed with autism \[[@pone.0231059.ref031]\]. And finally, B4GALT1 has been linked with developmental disorders \[[@pone.0231059.ref032]\]. The pathway R-HSA-5683371 is linked to the eye disease microphthalmia. It is known that schizophrenia is linked to eye abnormalities \[[@pone.0231059.ref033]\]. Among the 28 genes involved in that pathway, 12 have been linked to the disease in the literature (GOT2, PDHA1, DLD, GCSH, DLAT, PDHB, DAO, OGDH, DHTKD1, GNMT, DDO, PRODH2).

These results show the relevance of our framework for de novo disease--pathway associations prediction despite relatively low retrieval scores against the ground--truth.

2.3 Our GPD model predicts disease--disease relationships {#sec011}
---------------------------------------------------------

We rank disease--disease pairs based on the score described in Section 1.3 and test our results against a high confidence co-morbidity disease network obtained from a large cohort study by Hidalgo *et al*. \[[@pone.0231059.ref012]\]. We compare our method against DMSN network \[[@pone.0231059.ref015]\], restricted to our set of diseases, and three alternatives baselines. For the first alternative, we compute disease--disease association score using our approach defined in Section 1.3 on the trained MLR network, representing each disease by the top 300 highest scoring genes (which gave the best results based on grid search). The final two baselines associate to each disease--disease pair a Jaccard Index score based on 1) the set of genes associated to each disease in DisGeNET \[[@pone.0231059.ref025]\] and 2) the set of pathways associated to each disease in CTD database \[[@pone.0231059.ref030]\]. The results of the comparison are presented using a precision--recall curve (see [Fig 2](#pone.0231059.g002){ref-type="fig"}).

![Precision--recall (top) and ROC (bottom) curves of the test against the disease co-morbidity network built by Hidalgo *et al*. \[[@pone.0231059.ref012]\].](pone.0231059.g002){#pone.0231059.g002}

We observe that our approach outperform convincingly the other approaches in the task of retrieving existing co-morbidity links between diseases with over 10% increase compared to DMSN and 30% improvement over DisGeNET in terms of area under the precision--recall curve (auprc). These results strongly support our methodology. The scoring based on disease--gene is performing better than disease--pathway, hence we investigate the top 10 scoring disease--disease associations derived from it (see [Table 6](#pone.0231059.t006){ref-type="table"}).

10.1371/journal.pone.0231059.t006

###### Top 10 disease--disease links predicted using our approach based on the trained GPD.

![](pone.0231059.t006){#pone.0231059.t006g}

  Disease 1                     Disease 2
  ----------------------------- -----------------------------
  Atrial fibrillation           Vitiligo
  Atrial fibrillation           Peripheral vascular disease
  Alcoholic hepatitis           Osteosarcoma
  Rhabdoid cancer               Medulloblastoma
  Cornelia de Lange syndrome    Vitiligo
  Peripheral vascular disease   Vitiligo
  Atrial fibrillation           Osteosarcoma
  Leishmaniasis                 Alcoholic hepatitis
  Sotos syndrome                Vitiligo
  Follicular lymphoma           Osteosarcoma

We present and discuss below literature support for the predicted associations between the diseases.

Atrial fibrillation has been linked in the literature to thyroid disease \[[@pone.0231059.ref034]\] which is known to be co-morbid with vitiligo \[[@pone.0231059.ref035]\]. Atrial fibrillation and peripheral vascular disease are well known co-morbid conditions \[[@pone.0231059.ref036]\]. Alcoholism has been linked to the onset of some cancers notably implicating the transcription factor Nanog which itself has been linked to osteosarcoma \[[@pone.0231059.ref037]\]. Additionally, a drug used to treat alcoholism, Disulfiram, has recently been proposed as a potential treatment for osteosarcoma \[[@pone.0231059.ref038]\]. Those information put together suggest shared molecular background for the two conditions. Rhabdoid cancer is a rare form of aggressive cancer affecting young children and with very poor prognostic, which makes it difficult to evaluate co-morbid conditions. However, rhabdoid cancer is frequently mistaken for medulloblastoma indicating some similarity \[[@pone.0231059.ref039]\]. We found no evidence in the literature supporting a connection between the rare Cornelia de Lange syndrome and Vitiligo. Some studies have observed significant co-morbidity between vitiligo and psoriasis and the combination of the two has been linked to cardiovascular diseases, which include peripheral vascular disease \[[@pone.0231059.ref035], [@pone.0231059.ref040]\]. Atrial fibrillation and cardiac complications have been observed as the result of osteosarcoma \[[@pone.0231059.ref041], [@pone.0231059.ref042]\]. Leishmaniasis and alcoholic hepatitis are an unlikely co-morbid connection since it would require a patient both to have been infected by parasites of the Leishmania type and have had excessive alcohol intake. However, both disease affects the liver and leishmaniasis has sometimes been misdiagnosed for cirrhosis \[[@pone.0231059.ref043]\] which suggests that the two diseases might share some similar molecular processes that we would be capturing here. A case of co-occurence of Sotos syndrome and vitiligo has been reported in the medical literature \[[@pone.0231059.ref044]\]. It has been postulated that non-Hodgkin's lymphoma (which include follicular lymphoma) and osteosarcoma share underlying mechanisms \[[@pone.0231059.ref045]\]. Additionally, miR-202 has been identified as a potential tumor suppressor for both conditions \[[@pone.0231059.ref046]\].

Through this analysis, we have shown that most predicted pairs have either been observed co-occurring or can be connected through underlying mechanisms, thus validating our approach.

3 Conclusions {#sec012}
=============

In this study, we propose a multi-scale neural-network based framework that integrates gene expression data associated to diseases with gene--pathway information. Our integrative framework allows for simultaneously uncovering novel disease-disease associations and disease molecular mechanisms from patient gene expression profiles through the analysis of trained neural networks. We show that GPD achieve good diagnosis prediction on our dataset showing the validity of our integrative process. Furthermore, we show that the associations predicted from the trained models are biologically meaningful and supported by the literature, thus validating our approach.

While our disease molecular mechanisms are supported by the current knowledge about these diseases, a next step would be to identify among the predicted genes and pathways suitable biomarkers and drug targets that could be used to improve diagnosis, prognosis, and treatment. We leave this for future work. Also, while our multi-scale NN framework integrates the hierarchical functional organization of a cell (from genes to biological pathways), our methodology can be extended to include any dataset pertaining to diseases of interest, e.g., uncovering molecular mechanisms of cancer from patient somatic mutation profiles or linking diseases to non-coding RNA.

Finally, while we focus on patient data with application to diseases, our methodology can be extended to integrate additional omics data with the objective of getting more biologically accurate models for the analyses of patients, tissues, and cells. Some further applications include studies of diseases linked to a specific tissue, studies of cell's specialization, and any study that can benefit from the integration of the hierarchical functional organization of cells.

Supporting information {#sec013}
======================

###### Supplementary methods, figures, and tables.

**Project webpage** <https://life.bsc.es/iconbi/MultiScaleNN/index.html>.

(PDF)

###### 

Click here for additional data file.

10.1371/journal.pone.0231059.r001
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Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Carlo Vittorio Cannistraci

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Dear Authors

Congratulations

You article requires only a minor revision.

Best

CVC

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In your Data Availability statement you have specifed:

\"The processed data and all result data are available online at [\" ext-link-type=\"uri\" xlink:type=\"simple\"\>https://life.bsc.es/iconbi/MultiScaleNN\"](https://life.bsc.es/iconbi/MultiScaleNN).

But this link can not be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.

Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Really interesting work from the authors, which trained a neural network-based method with prior biological knowledge and whose architecture is based on molecular organization with one hidden layer representing gene-pathway links.

The purpose of the NN model is to unveil disease-gene, disease-pathway and disease-disease associations. Therefore, the authors termed it GPD (for Gene, Pathway and Disease). From a selected dataset of patient-disease interaction (one patient had one disease), GPD was compared to other NN model based on multinomial logistic regression (MLR), random forest, naïve bayes and support vector machine classifiers in the task for patient-disease classification. The MLR model outperformed the rest of the methods followed by GPD. The authors state that this might be due to two main factors: the degree of freedom of MLR which is \~4 times higher than GPD, and that the biological information from where GPD was trained is noisy and incomplete. Nonetheless, valuable biological information can be extracted from the trained GPD model, where literature-validated associations between disease-gene, disease-pathway and disease-disease were found.

Minor comments:

1.In the introduction section, line 20: "In specific cancers, Abeel et al. \[6\] use support vector machines and ensemble feature selection methods to select putative gene biomarkers."

You might consider also to refer to articles that show methods that can work on different omic signatures for cancer in general like Ciucci et al., 2017 Scientific reports.

2.The authors gave an association score for the prediction of disease-disease, disease-pathway and disease-gene relationships, which was lately use to obtain the highest 10 predictions under the three mentioned relationships, validating the predictions by literature search. It would be interesting to known the extent to which this score is "high-enough" to obtain valuable information from the trained GPD model, since this score magnitude is not mentioned on the manuscript.

Reviewer \#2: === General Comments

The authors present a neural network incorporating pathway information for disease classification based on differentially expressed genes. The core of the work is less the correct prediction than the interpretation of the network\'s choice and thus enabling the deciphering of disease-disease networks and a shift in the causal direction. The paper gives a comprehensive introduction into existing work, is well written and scientifically sound. The developed method is compared against a Multi-label logistic regression baseline model. The model itself was trained following common standards with early stopping as regularization based on a cross-validation.

=== Minor Comments

\* The authors should clarify their method for the prediction of disease-(disease/pathway/gene) relationships. What is meant with the intensity of local variation of d with respect to perturbation of u? Are there thresholds involved, e.g., when is the intensity high enough to create the relationship.

\* Regularization: The authors utilize early stopping, but no other regularization. Here, particular considering the number of genes vs. the number of samples might pose a problem. Have the authors considered heavy drop-out regularization of the input layer, which might boost the necessity to use the pathway layer since it cannot any longer rely on the presence of single genes?

\* Connected to the point above, the authors should depict the learning behavior of their network wrt. the loss training vs. validation. Is the observed behavior expected, or does it indicate over- or underfitting.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0231059.r002

Author response to Decision Letter 0

13 Feb 2020

Dear Editor,

Thank you for inviting us to submit a revised version of our manuscript titled "Unveiling new disease, pathway, and gene associations via multi-scale neural network".

We revised our paper to address the reviewers' suggestions. Our responses to the reviewers' comments are summarized below.

We believe that the manuscript is now suitable for publication in PloS One, and look forward to hearing from you.

Sincerely yours,

Nataša Pržulj

Reviewer 1:

1\. In the introduction section, line 20: "In specific cancers, Abeel et al. \[6\] use support vector machines and ensemble feature selection methods to select putative gene biomarkers."

You might consider also to refer to articles that show methods that can work on different omic signatures for cancer in general like Ciucci et al., 2017 Scientific reports.

Response: We followed the suggestion of the reviewer and in our revised manuscript we updated the introduction accordingly (page 2, paragraph 1).

2\. The authors gave an association score for the prediction of disease-disease, disease-pathway and disease-gene relationships, which was lately use to obtain the highest 10 predictions under the three mentioned relationships, validating the predictions by literature search. It would be interesting to known the extent to which this score is "high-enough" to obtain valuable information from the trained GPD model, since this score magnitude is not mentioned on the manuscript.

Response: We thank the reviewer for the comment. There is no out-of-the-box threshold that can answer this question and we chose here to validate our scoring strategy with manual literature curation and precision-recall analysis against an independent ground-truth. However, one could use the precision-recall analysis we ran as a way to estimate how many of the top scoring associations can be considered relevant. We adjusted the main to reflect this. (page 4, paragraph 5)

Reviewer 2:

1\. The authors should clarify their method for the prediction of disease-(disease/pathway/gene) relationships. What is meant with the intensity of local variation of d with respect to perturbation of u? Are there thresholds involved, e.g., when is the intensity high enough to create the relationship.

Response: We thank the reviewer for the comment. The score used to identify molecular links to the disease rests on the analysis of variations of the output of a function (e.g., a neural network or part of one) with respect to the variation of one of its input (e.g., gene expression). Intuitively, we assume that the trained neural network links a gene, for instance, to a disease if a change in the expression of the gene leads to a variation in the disease score given by the output of the neural network. Effectively, this is the analytical equivalent of manually varying the expression of each gene and measuring the impact on the score and prediction of each disease. We postulate here that the higher the induced variation, the more likely there is an actual biological connection between the gene and disease. To assess this, we rank disease-gene pairs based on this score and we evaluate how well this ranking captures known interactions with precision-recall and receiver operating characteristic analysis as well as manual literature curation. We updated the manuscript to clarify those points. (page 4, paragraph 5)

The second part of the comment relating to threshold is the same as the second comment of the first reviewer and we refer the reader to the response above.

2\. Regularization: The authors utilize early stopping, but no other regularization. Here, particular considering the number of genes vs. the number of samples might pose a problem. Have the authors considered heavy drop-out regularization of the input layer, which might boost the necessity to use the pathway layer since it cannot any longer rely on the presence of single genes?

Response: We thank the reviewer for the suggestion. We had investigated the addition of L2 and L1 regularisations with a cross-validation but observed that the models without were performing better in terms of cross-entropy loss thus we removed any. Heavy dropout on the input layer was not investigated, following the reviewer suggestion, we have run test with it and observed that similarly it was not leading to improvements in terms of cross-entropy loss or overfitting. We updated the text to mention the tests with addition of L1, L2, or dropout regularisations and added a supplementary table with cross-validation scores for each regularisation. (page 4, paragraph 3 and Supplementary Table 2)

3\. Connected to the point above, the authors should depict the learning behavior of their network wrt. the loss training vs. validation. Is the observed behavior expected, or does it indicate over- or underfitting.

Response: We followed the reviewer suggestion, and in our revised manuscript we show the learning behaviour of the neural networks (Supplementary Figures 1 and 2). Indeed, the plots suggest some overfitting, however, as mentioned above, the performances remain better than when regularisation is added to address the overfitting.
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16 Mar 2020

Unveiling new disease, pathway, and gene associations via multi-scale neural networks

PONE-D-19-28184R1

Dear Authors

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Carlo Vittorio Cannistraci

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The Authors addressed all minor concerns of the reviewers and the article is accepted.

Reviewers\' comments:
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Unveiling new disease, pathway, and gene associations via multi-scale neural network

Dear Dr. Gaudelet:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Carlo Vittorio Cannistraci

Academic Editor

PLOS ONE
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